A share price of PTC Therapeutics Inc [PTCT] is currently trading at $46.94, up 4.13%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The PTCT shares have gain 18.03% over the last week, with a monthly amount drifted -17.89%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
PTC Therapeutics Inc [NASDAQ: PTCT] stock has seen the most recent analyst activity on March 11, 2025, when BofA Securities upgraded its rating to a Neutral and also boosted its price target to $55 from $41. Previously, Scotiabank started tracking the stock with Sector Perform rating on March 07, 2025, and set its price target to $55. On December 13, 2024, upgrade upgraded it’s rating to Overweight and revised its price target to $67 on the stock. RBC Capital Mkts upgraded its rating to a Outperform and increased its price target to $63 on December 03, 2024. Robert W. Baird started tracking with a Outperform rating for this stock on September 04, 2024, and assigned it a price target of $44.
PTC Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $24.00 and $58.38. Currently, Wall Street analysts expect the stock to reach $55 within the next 12 months. PTC Therapeutics Inc [NASDAQ: PTCT] shares were valued at $46.94 at the most recent close of the market. An investor can expect a potential return of 17.17% based on the average PTCT price forecast.
Analyzing the PTCT fundamentals
Trailing Twelve Months sales for PTC Therapeutics Inc [NASDAQ:PTCT] were 806.78M which represents -30.58% decline. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -0.37%, Pretax Profit Margin comes in at -0.45%, and Net Profit Margin reading is -0.45%. To continue investigating profitability, this company’s Return on Assets is posted at -0.21, Equity is 0.36 and Total Capital is -0.26. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-2.25.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 44.81 points at the first support level, and at 42.69 for the second support level. However, for the 1st resistance point, the stock is sitting at 48.83, and for the 2nd resistance point, it is at 50.73.
Ratios To Look Out For
To put it in perspective, the Current Ratio for PTC Therapeutics Inc [NASDAQ:PTCT] is 2.35. As well, the Quick Ratio is 2.31, while the Cash Ratio is 1.34. Considering the valuation of this stock, the price to sales ratio is 4.59.
Transactions by insiders
Recent insider trading involved Golden Lee Scott, EVP & CHIEF MEDICAL OFFICER, that happened on Apr 02 ’25 when 897.0 shares were sold. Officer, Golden Lee Scott completed a deal on Apr 02 ’25 to buy 897.0 shares. Meanwhile, CHIEF BUSINESS OFFICER Pauwels Eric sold 6762.0 shares on Mar 17 ’25.
